Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892211053> ?p ?o ?g. }
- W2892211053 endingPage "702" @default.
- W2892211053 startingPage "692" @default.
- W2892211053 abstract "The pharmacokinetics of oxycodone in patients with end-stage renal disease (ESRD) requiring haemodialysis are largely unknown. Therefore, we investigated the pharmacokinetics of oxycodone/naloxone prolonged release and their metabolites in patients with ESRD during and between haemodialysis sessions. Single doses of oxycodone/naloxone (5/2.5 or 10/5 mg) were administered in nine patients with ESRD using a cross-over design on the day of dialysis and on a day between dialysis sessions. Plasma, dialysate and urine concentrations of oxycodone, naloxone and their metabolites were determined up to 48 h post-dosing using a liquid chromatography–tandem mass spectrometry system. Haemodialysis performed 6–10 h after dosing removed ∼10% of the administered dose of oxycodone predominantly as unconjugated oxycodone and noroxycodone or conjugated oxymorphone and noroxymorphone. The haemodialysis clearance of oxycodone based on its recovery in dialysate was (mean ± SD) 8.4 ± 2.1 L/h. The geometric mean (coefficient of variation) plasma elimination half-life of oxycodone during the 4-h haemodialysis period was 3.9 h (39%) which was significantly shorter than the 5.7 h (22%) without haemodialysis. Plasma levels of the active metabolite oxymorphone in its unconjugated form were very low. Oxycodone is removed during haemodialysis. The pharmacokinetics including the relatively short half-life of oxycodone in patients with ESRD with or without haemodialysis and the absence of unconjugated active metabolites indicate that oxycodone can be used at usual doses in patients requiring dialysis." @default.
- W2892211053 created "2018-09-27" @default.
- W2892211053 creator A5014397988 @default.
- W2892211053 creator A5024133720 @default.
- W2892211053 creator A5040957114 @default.
- W2892211053 creator A5042138221 @default.
- W2892211053 creator A5045516878 @default.
- W2892211053 creator A5045595147 @default.
- W2892211053 creator A5050574666 @default.
- W2892211053 creator A5058024716 @default.
- W2892211053 creator A5071531513 @default.
- W2892211053 creator A5071962736 @default.
- W2892211053 creator A5079797502 @default.
- W2892211053 creator A5087882435 @default.
- W2892211053 creator A5088856996 @default.
- W2892211053 date "2018-09-05" @default.
- W2892211053 modified "2023-09-27" @default.
- W2892211053 title "Pharmacokinetics of oxycodone/naloxone and its metabolites in patients with end-stage renal disease during and between haemodialysis sessions" @default.
- W2892211053 cites W1568078031 @default.
- W2892211053 cites W1574320663 @default.
- W2892211053 cites W1955305547 @default.
- W2892211053 cites W1964678251 @default.
- W2892211053 cites W1965541116 @default.
- W2892211053 cites W1965767928 @default.
- W2892211053 cites W1968660519 @default.
- W2892211053 cites W1979997745 @default.
- W2892211053 cites W1987740031 @default.
- W2892211053 cites W1994458277 @default.
- W2892211053 cites W1997637982 @default.
- W2892211053 cites W1999452693 @default.
- W2892211053 cites W2007899880 @default.
- W2892211053 cites W2008275924 @default.
- W2892211053 cites W2013235742 @default.
- W2892211053 cites W2024592581 @default.
- W2892211053 cites W2031962926 @default.
- W2892211053 cites W2032990701 @default.
- W2892211053 cites W2042846329 @default.
- W2892211053 cites W2052921140 @default.
- W2892211053 cites W2054011994 @default.
- W2892211053 cites W2058501869 @default.
- W2892211053 cites W2060478811 @default.
- W2892211053 cites W2064527612 @default.
- W2892211053 cites W2069373046 @default.
- W2892211053 cites W2085353410 @default.
- W2892211053 cites W2104983310 @default.
- W2892211053 cites W2106723549 @default.
- W2892211053 cites W2124990868 @default.
- W2892211053 cites W2131684444 @default.
- W2892211053 cites W2143443866 @default.
- W2892211053 cites W2146310716 @default.
- W2892211053 cites W2164312789 @default.
- W2892211053 cites W2288692386 @default.
- W2892211053 cites W2321585154 @default.
- W2892211053 cites W2410411229 @default.
- W2892211053 cites W2527512553 @default.
- W2892211053 cites W2758032729 @default.
- W2892211053 cites W2773864321 @default.
- W2892211053 cites W4232375907 @default.
- W2892211053 cites W4361806722 @default.
- W2892211053 doi "https://doi.org/10.1093/ndt/gfy285" @default.
- W2892211053 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30189012" @default.
- W2892211053 hasPublicationYear "2018" @default.
- W2892211053 type Work @default.
- W2892211053 sameAs 2892211053 @default.
- W2892211053 citedByCount "8" @default.
- W2892211053 countsByYear W28922110532019 @default.
- W2892211053 countsByYear W28922110532020 @default.
- W2892211053 countsByYear W28922110532021 @default.
- W2892211053 countsByYear W28922110532022 @default.
- W2892211053 crossrefType "journal-article" @default.
- W2892211053 hasAuthorship W2892211053A5014397988 @default.
- W2892211053 hasAuthorship W2892211053A5024133720 @default.
- W2892211053 hasAuthorship W2892211053A5040957114 @default.
- W2892211053 hasAuthorship W2892211053A5042138221 @default.
- W2892211053 hasAuthorship W2892211053A5045516878 @default.
- W2892211053 hasAuthorship W2892211053A5045595147 @default.
- W2892211053 hasAuthorship W2892211053A5050574666 @default.
- W2892211053 hasAuthorship W2892211053A5058024716 @default.
- W2892211053 hasAuthorship W2892211053A5071531513 @default.
- W2892211053 hasAuthorship W2892211053A5071962736 @default.
- W2892211053 hasAuthorship W2892211053A5079797502 @default.
- W2892211053 hasAuthorship W2892211053A5087882435 @default.
- W2892211053 hasAuthorship W2892211053A5088856996 @default.
- W2892211053 hasBestOaLocation W28922110532 @default.
- W2892211053 hasConcept C112705442 @default.
- W2892211053 hasConcept C126322002 @default.
- W2892211053 hasConcept C170493617 @default.
- W2892211053 hasConcept C2776029756 @default.
- W2892211053 hasConcept C2776316548 @default.
- W2892211053 hasConcept C2777288759 @default.
- W2892211053 hasConcept C2778063415 @default.
- W2892211053 hasConcept C2778750930 @default.
- W2892211053 hasConcept C2779978075 @default.
- W2892211053 hasConcept C2781063702 @default.
- W2892211053 hasConcept C3019040382 @default.
- W2892211053 hasConcept C42219234 @default.
- W2892211053 hasConcept C71924100 @default.
- W2892211053 hasConcept C98274493 @default.